Navigating innovation and market disruption in Parkinson’s Disease landscape
DRG Disease Landscape & Forecast
Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7) – This report offers a deep dive into the dynamic Parkinson’s disease market, where innovation is tempered by disruption. It analyzes key developments, such as the launch of AbbVie’s Vyalev/Produodopa and the withdrawal of Sunovion’s Kynmobi, while examining regulatory delays facing SPN-830 and IPX-203. With generics dominating all drug classes, it highlights the tough path for new brands lacking clinical differentiation in an increasingly competitive landscape.
Request more information
What is Disease Landscape & Forecast?
Disease Landscape & Forecast is a premier market intelligence platform, offering:
- Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts
- Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year
- Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis
Key trends in Parkinson’s Disease treatment:
- Product launches and withdrawals: Introduction of new brands like Inbrija and Vyalev/Produodopa, alongside setbacks such as Kynmobi’s withdrawal and temporary discontinuation of Ongentys.
- Regulatory challenges: Delays in the approval and launch of promising therapies, including SPN-830 and IPX-203, affecting market entry timing.
- Intensifying competition in a generic-dominated market: Challenges new brands face due to cost sensitivity, lack of clinical differentiation, and widespread availability of generics across PD drug classes.
- Evolving treatment landscape and complexity: Increasing complexity in the treatment algorithm as more therapies target motor fluctuations, dyskinesia, dementia and acute “off” episodes.
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key questions answered:
- How will the launch of advanced levodopa reformulations—such as Vyalev, ND-0612, and IPX-203—reshape clinical practice and market dynamics?
- What are neurologists’ perceptions of emerging adjunctive therapies for managing motor fluctuations, dyskinesia, and cognitive symptoms?
- Which disease-modifying candidates are gaining traction and hold the greatest potential to shift the treatment paradigm?
- How are acute rescue therapies for ‘off’ periods being integrated into care, and where do key opportunities remain for novel symptom-targeting agents?
Preview only – some data has been intentionally blurred for confidentiality. Full data available in the report.
Key highlights:
10-year market forecast (2023 – 2033)
Annualized detailed forecasts and treatment trends across the U.S., EU5, and Japan.
Granular epidemiological insights
Features prevalence data by country, with diagnosis and treatment rates segmented by population to support targeted market analysis.
Pipeline intelligence powered by Cortellis
Real-time updates on current and emerging therapies, including novel drug classes.
Primary research with 25 experts
Specific interviews with thought-leading neurologists - experts' perspectives complemented by proprietary survey data from Clarivate broader research initiatives.